Funding for this research was provided by:
FRAXA Research Foundation
Text and Data Mining valid from 2019-10-16
Received: 18 April 2018
Accepted: 9 September 2019
First Online: 16 October 2019
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board at Rush University Medical Center. Informed written consent was obtained from either the participant or the parent/legal guardian prior to participation, and assent was obtained from each participant who was not his/her own legal guardian.
: Consent for publication is not applicable.
: EBK has subsequently received funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, Marinus, Ovid, Zynerba, GW, and Neurotrope Pharmaceuticals to consult on trial design or development strategies and/or conduct clinical trials in FXS, Rett syndrome, or Down syndrome, from Vtesse to conduct clinical trials in NP-C, and from Asuragen Inc. to develop testing standards for FMR1 testing. The other authors declare that they have no competing interests.